<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1366">
  <stage>Registered</stage>
  <submitdate>7/11/2006</submitdate>
  <approvaldate>7/11/2006</approvaldate>
  <nctid>NCT00397098</nctid>
  <trial_identification>
    <studytitle>Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder</studytitle>
    <scientifictitle>A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A.</scientifictitle>
    <utrn />
    <trialacronym>VEGA</trialacronym>
    <secondaryid>EudraCT 2006-002253-71</secondaryid>
    <secondaryid>LTE5894</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anxiety Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SR58611A

Treatment: drugs: SR58611A


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary criterion is the time to relapse of anxious symptoms (in days) from randomization date defined by either:</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>HAM-A total score = 15 confirmed at a subsequent visit 2 weeks later unless the patient drops out,or</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Any drop-out for lack of efficacy (according to investigator's decision),or</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Prescription/use of alternative or additional treatments for relief of psychiatric symptoms.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline (V7) in:-Clinical Global Impression (CGI) Severity of Illness Score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Anxiety Rating Scale (HAM-A)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For entry into the open phase:

          -  Patients suffering from generalized anxiety disorder, according to Diagnostic and
             Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and assessed with the Mini
             International Neuropsychiatric Interview (MINI) plus Generalized Anxiety Disorder
             (GAD) module.

          -  With a total score on the 14-item Hamilton Anxiety Rating Scale (HAM-A) &gt; 20 at
             V1(D-4) and V2 (D-1).

        For entry into the double-blind randomized phase:

          -  Improved patients with HAM-A score &lt; 11 at V7 (W12).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inpatients.

          -  Patients with a diagnosis of Major Depressive Disorder (DSM IV-TR) within 6 months of
             screening.

          -  Patients with a MADRS total score &gt; 18 at screening or baseline.

          -  Patients at immediate risk for suicidal behaviour.

          -  Patients with other current (within 6 months) anxiety disorder according to the MINI

          -  Patients with a lifetime history according to the MINI of: Bipolar disorder, Psychotic
             disorder, Antisocial personality disorder.

          -  Patients with a current history according to the MINI of: Anorexia nervosa or bulimia
             nervosa in the past 6 months, Alcohol or substance dependence or abuse in the past 12
             months, except nicotine or caffeine dependence.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>257</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis Administrative Office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the efficacy and safety of SR58611A (350 mg BID)
      compared to placebo in the prevention of relapse of anxiety, in patients with Generalized
      Anxiety Disorder improved after 12 weeks of treatment with SR58611A.

      The primary objective is to evaluate the efficacy of SR58611A 350mg BID compared to placebo
      over a 24 to 52-week treatment period.

      The secondary objective is to assess the safety and tolerability of SR58611A in patients with
      GAD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00397098</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>